Prostate cancer has been one of the major areas of research for radioligand therapies. Last year, Novartis officials estimated that the March 28, 2025, FDA approval for Pluvicto in metastatic ...

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study published ...

A supplement made from broccoli, green tea, and turmeric has slowed the rise of a prostate cancer blood marker in men monitored for early disease. That slowdown reframes how long some patients may ...

A new blended genome genetic test being studied in a major clinical trial may help identify men at highest risk of aggressive prostate cancer and personalise screening strategies.

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.

Until recently, the treatment of metastatic castration-resistant prostate cancer (mCRPC) relied exclusively on hormonal therapies and taxane chemotherapy. The advent of modern molecular profiling ...

For the first time ever, researchers from the Norwegian University of Science and Technology (NTNU) have identified new ...

TULSA reduces tumor volume and PSA levels, improving urinary and sexual function in prostate cancer patients. Five-year TACT study data shows 80% of patients had no significant disease after one year, ...

A plant-based diet combined with probiotics reduces PSA increase in men and lowers prostate cancer risk by 3x.